Kenneth Westover, MD, PhD, Associate Professor of Radiation Oncology and Biochemistry

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Vibliome Therapeutics
    Topic: 
    Early stage drug discovery
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Amgen
    Topic: 
    KRAS G12C inhibitors
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Revolution Medicines
    Topic: 
    KRAS inhibitors
    Date added: 
    01/04/2022
Return to 162 Thoracic Oncology Tumor Board Conference (031822)